Article Text
Statistics from Altmetric.com
To address the raise in Mpox cases, in July 2022, Germany started a pre-exposure or postexposure vaccination programme with the modified vaccinia Ankara virus vaccine (Imvanex/Jynneos).1 As this is a live vaccine, there are constrains for certain patient groups. Current indications for interleukin (IL) 23 antibodies advise against the simultaneous use of live vaccines and recommend a 21-week washout after antibody therapy.2
We report on a 38-year-old HIV-negative man who was receiving treatment with the anti-IL-23 antibody risankizumab (150 mg every 3 months) for psoriasis vulgaris when he was assessed to be at high risk for Mpox. He had not previously received …
Footnotes
Handling editor Anna Maria Geretti
Contributors H-HL planned, conducted and reported the work described in the article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.